Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4945600 | 0.86 | ALDH1A1 (0.67) | SLC9A1LMNAKMT2AMAPTALDH1A1 | |
| SCHEMBL25002899 | 0.85 | ALDH1A1 (0.65) | SLC9A1LMNAMAPTALDH1A1HPGD | |
| SCHEMBL21981938 | 0.82 | HTT (0.67) | LMNAKMT2AMAPTALDH1A1HPGD | |
| SCHEMBL4942898 | 0.81 | SLC9A1 (0.59) | SLC9A1LMNAKMT2AMAPTALDH1A1 | |
| SCHEMBL3065831 | 0.81 | RPA1 (0.64) | SLC9A1LMNAKMT2AMAPTALDH1A1 | |
| SCHEMBL4945642 | 0.80 | SLC9A1 (0.57) | SLC9A1LMNAKMT2AALDH1A1HTT | |
| SCHEMBL3059132 | 0.77 | ALDH1A1 (0.62) | SLC9A1LMNAKMT2AALDH1A1HPGD | |
| SCHEMBL4946520 | 0.76 | S1PR4 (0.62) | SLC9A1MAPTALDH1A1S1PR4KDM4E | |
| SCHEMBL6829658 | 0.76 | HTT (0.45) | LMNAKMT2AMAPTALDH1A1HPGD | |
| SCHEMBL4943742 | 0.76 | HTT (0.51) | KMT2AMAPTALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351843-B2 | Furancarbonylguanidine derivatives, their preparation and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-04-01 | — | — | US | disclosed |
| US-20070299131-A1 | Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-12-27 | — | — | US | disclosed |
| EP-1697335-A1 | FURANCARBONYLGUANIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005063727-A1 | FURANCARBONYLGUANIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299131-A1 | Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them | SLC9A1, NHERF1, SLC5A1 | SLC9A1 1/4885LMNA 4022/4885KMT2A 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.